To determine whether inhibition of TRPV1+ visceral afferents could prevent colitis-induced microglial activation and VHS, TRPV1-hM4Di and hM4Di littermate control mice were treated with 2.5% DSS for 7 days and received either saline or chronic CNO treatment (Figure 4A). The gene discussed is TRPV1; the disease is colitis.